Anti-nucleolin antibodies with potential widespread clinical utility.

CharlestonPharma has obtained in vitro, ex vivo and in vivo proof of concept for its first-in-class fully human monoclonal antibodies that specifically target nucleolin located in the plasma membrane and cytoplasm of tumor cells. Research in our laboratories (1-8) and those of others (9-14) have demonstrated the highly selective localization of nucleolin in these extra-nuclear compartments of many types of human tumors compared to the corresponding normal tissues. These results are consistent with our preclinical studies which show that our nucleolin-specific antibodies have broad spectrum anticancer activity with limited or no toxicity to normal human cells.